Navigation Links
US Dermatophytic Onychomycosis Market Discussed by GlobalData in Topical Report Now Available at MarketPublishers.com
Date:7/17/2013

London, UK (PRWEB) July 17, 2013

Dermatophytic onychomycosis (DO) is one of the most widespread fungal nail infections. It is not considered to be a life-threatening disease, but it can cause considerable pain and discomfort. At present, DO therapies consist of generics which are quite effective but are not as safe as their brand-name counterparts.

New topical DO therapies are predicted to be introduced in the offing, and they are likely to scale up the total drug treatment rates in the US owing to increasing physicians’ awareness of safer and more effective treatment options. Meanwhile, given their advantages such as a shorter duration of treatment, generic therapies represent a challenge to the development of the innovative therapies.

Topical research report “PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022” elaborated by GlobalData has been recently published by Market Publishers Ltd.

Report Details:

Title: PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
Published: June, 2013
Pages: 146
Price:    US$ 4,995.00
http://marketpublishers.com/report/pharmaceuticals/drugs/dermatophytic-onychomycosis-do-us-drug-forecast-n-market-analysis-to-2022.html

The report provides in-depth insights into the US DO market. It uncovers vital general information on DO including its epidemiology, key symptoms and disease treatment; and also discloses historical and present data on the DO market revenues, annual therapy costs, treatment usage patterns, etc. The study contains a comprehensive pipeline analysis, evaluates the competitive environment, and presents details on the top companies operating in the market. The report examines major market drivers and restraints, outlines the market opportunities and challenges, characterizes prevailing development trends, and moreover, sheds light on the possible path of the market development through 2022.

Report Scope:

  •     Comprehensive overview of DO (epidemiology, general symptoms, disease treatment recommendations, etc.).
  •     All-round analysis of the US DO market.
  •     Historical and present data on the market performance.
  •     Description of the competitive scenario.
  •     Vital information on the major market opportunities.
  •     Clinical pipeline assessment.
  •     Profiles of the leading market players.
  •     Discussion of the important industry issues.
  •     Examination of the factors driving and restraining the market development.
  •     Detailed future market forecast up to 2022.

More research studies by the publisher can be found at GlobalData page.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10937702.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
7. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
8. GeneLink Marketing Efforts Poised to Show Results
9. Animal Biotechnology - Technologies, Markets and Companies
10. Gene Therapy - Technologies, Markets and Companies
11. Biomarkers - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):